MASI earnings

Masimo Corporation (NASDAQ:MASI) ("Masimo"), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE:DHR) ("Danaher") will acquire Masimo for $180.00 per share in cash, representing a total consideration of $9.9 billion (the "Transaction"). The Transaction has been unanimously approved by both Masimo's Board of Directors and Danaher's Board of Directors. Masimo will become a standalone business unit and brand within Danaher's Diagnostics segment and will operate autonomously while strengthening Danaher's offering in acute care settings. Katie Szyman, Chief Executive Officer of Masimo, stated: "We loo

Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release fourth quarter and full year 2025 financial results for the period ended January 3, 2026, after the market closes on Thursday, February 26, 2026. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call or the webcast, please use the link below. Upon registering, each participant will be provided with details for the call or webcast. Conference Call Registration Link (Please register to obtain the dial-in number): Masim

Complete fourth quarter and full-year 2025 financial results will be announced on Thursday, February 26, 2026 Masimo Corporation (NASDAQ:MASI) today announced select preliminary financial results for the fourth quarter and full-year ended January 3, 2026. Preliminary Fourth Quarter 2025 Financial Results:   •   Revenue is expected to be approximately $411 million, representing approximately 12% growth on a reported basis and 11% growth on a constant currency basis(1);   •   Non-GAAP earnings per diluted share(2), including the impact of new tariffs, are expected to be more than $1.54; and   •   Shipments of noninv

Masimo Corporation (NASDAQ:MASI) today announced its financial results for the third quarter ended September 27, 2025. Third Quarter 2025 Results From Continuing Operations(1): GAAP revenue of $371.5 million, representing 8.2% growth on a reported basis; Non-GAAP revenue of $371.2 million, representing 7.6% growth on a constant currency basis(2); GAAP net income per diluted share of $0.99; and Non-GAAP net income per diluted share(2) of $1.32, representing 38% growth versus prior year period. Katie Szyman, Chief Executive Officer of Masimo, said, "In the third quarter, we saw continued positive momentum across our core healthcare business, driven by the power of our innovative pr

Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release third quarter 2025 financial results for the period ended September 27, 2025, after the market closes on Tuesday, November 4, 2025. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the call will also be sent to registered

Masimo Corporation (NASDAQ:MASI) today announced its financial results for the second quarter ended June 28, 2025. Second Quarter 2025 Results From Continuing Operations(1): GAAP revenue of $371 million, representing 8% growth on a reported basis; Non-GAAP revenue of $370 million, representing 7% growth on a constant currency basis(2); GAAP net income per diluted share of $0.82; and Non-GAAP net income per diluted share(2) of $1.33, which grew 46% versus prior year period. Katie Szyman, Chief Executive Officer of Masimo, said, "We once again delivered strong results in the second quarter as our core health care business continued to demonstrate strong growth and earnings. W

Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release second quarter 2025 financial results for the period ended June 28, 2025, after the market closes on Tuesday, August 5, 2025. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the call will also be sent to registered partic

Masimo Corporation (NASDAQ:MASI) today announced its financial results for the first quarter ended March 29, 2025. First Quarter 2025 Results From Continuing Operations(1): GAAP revenue of $372 million, representing 10% on a reported basis; Non-GAAP revenue of $371 million, representing 10% on a constant currency basis(3); GAAP net income per diluted of $0.86; and Non-GAAP net income per diluted share(3) of $1.36, which grew 56% versus prior year period. First Quarter 2025 Results From Discontinued Operations(2): GAAP loss from discontinued operations, net of tax was ($218) million, which included an impairment of intangibles of $295 million for the non-healthcare consumer busi

Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release first quarter 2025 financial results for the period ended March 29, 2025, after the market closes on Tuesday, May 6, 2025. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the call will also be sent to registered participant

Masimo (NASDAQ:MASI) today announced its financial results for the fourth quarter and full-year ended December 28, 2024 and provided updated estimates for its full-year 2025 guidance. Fourth Quarter 2024 Financial Results: Consolidated revenue was $601 million, representing 9% growth on a reported and constant currency basis(1); Healthcare revenue was $368 million, representing 8% growth on a reported basis and 9% growth on a constant currency basis(1); Non-healthcare revenue was $232 million, representing 11% growth on a reported and constant currency basis(1); GAAP net loss per basic share was ($6.52), which included an impairment of goodwill and intangibles for Sound United

Complete fourth quarter and full-year 2024 financial results will be announced on Tuesday, February 25, 2025 Masimo Corporation (NASDAQ:MASI) today announced select preliminary financial results for the fourth quarter and full-year ended December 28, 2024 and provided estimates for its full-year 2025 guidance. Preliminary Fourth Quarter 2024 Financial Results: Consolidated revenue is expected to be approximately $601 million, representing 9% growth on a reported and constant currency basis(1); Healthcare revenue is expected to be approximately $368 million, representing 8% growth on a reported basis and 9% growth on a constant currency basis(1); Non-healthcare revenue is expect

Third Quarter 2024 Highlights: Healthcare revenue of $343.3 million increased 11.5% on a reported basis and 11.7% on a constant currency basis(1); GAAP net income per diluted share was $0.18; and Non-GAAP(1) net income per diluted share was $0.98.   Masimo Corporation (NASDAQ:MASI) today announced its financial results for the third quarter ended September 28, 2024. Third Quarter 2024 Results Consolidated revenue was $504.6 million, comprised of healthcare revenue of $343.3 million and non-healthcare revenue of $161.3 million. Shipments of noninvasive technology boards and instruments were 60,500. GAAP operating income was $30.1 million and non-GAAP(1) operating income was $80.8

Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release third quarter 2024 financial results for the period ended September 28, 2024, after the market closes on Tuesday, November 5, 2024. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Michelle Brennan, interim Chief Executive Officer, Micah Young, Executive Vice President and Chief Financial Officer and Bilal Muhsin, Chief Operating Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a re

Second Quarter 2024 Highlights: Consolidated revenue was $496.3 million; Healthcare revenue was $343.9 million; Non-healthcare revenue was $152.4 million; GAAP net income per diluted share was $0.29; and Non-GAAP net income per diluted share was $0.86. Masimo Corporation (NASDAQ:MASI) today announced its financial results for the second quarter ended June 29, 2024. Second Quarter 2024 Results: Consolidated revenue was $496.3 million, comprised of healthcare revenue of $343.9 million and non-healthcare revenue of $152.4 million. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 58,600. Consolidated GAAP

Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release second quarter 2024 financial results for the period ended March 30, 2024, after the market closes on Tuesday, August 6, 2024. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the cal

First Quarter 2024 Highlights: Consolidated revenue was $492.8 million; Healthcare revenue was $339.6 million; Non-healthcare revenue was $153.2 million; GAAP net income per diluted share was $0.35; and Non-GAAP net income per diluted share was $0.77. Masimo Corporation (NASDAQ:MASI) today announced its financial results for the first quarter ended March 30, 2024. First Quarter 2024 Results: Consolidated revenue was $492.8 million, comprised of healthcare revenue of $339.6 million and non-healthcare revenue of $153.2 million. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 50,400. Consolidated GAAP o

Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release first quarter 2024 financial results for the period ended March 30, 2024, after the market closes on Tuesday, May 7, 2024. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the call wi

Fourth Quarter 2023 Highlights: Consolidated revenue was $548.9 million; Healthcare revenue was $339.9 million; Non-healthcare revenue was $209.0 million; GAAP net income per diluted share of $0.63; and Non-GAAP net income per diluted share (updated definition) of $1.25. Full-Year 2023 Highlights: Consolidated revenue was $2,048.1 million; Healthcare revenue was $1,275.5 million; Non-healthcare revenue was $772.6 million. GAAP net income per diluted share of $1.51; and Non-GAAP net income per diluted share (updated definition) of $3.79. Masimo (NASDAQ:MASI) today announced its financial results for the fourth quarter and full-year ended December 30, 2023.

Complete fourth quarter and full-year 2023 financial results will be announced on Tuesday, February 27, 2024 Masimo Corporation (NASDAQ:MASI) today announced select preliminary financial results for the fourth quarter and full-year ended December 30, 2023 and provided estimates for its full-year 2024 guidance. Preliminary Fourth Quarter 2023 Financial Results:   •   Consolidated revenue of $541 million to $551 million;   •   Healthcare revenue of $336 million to $341 million; and   •   Non-healthcare revenue of $205 million to $210 million. Preliminary Full-Year 2023 Financial Results:   •  

 Third Quarter 2023 Highlights Consolidated revenue was $478.9 million; Healthcare revenue was $307.8 million; Non-healthcare revenue was $171.1 million; GAAP net income per diluted share was $0.20; and Non-GAAP net income per diluted share was $0.63. Masimo Corporation (NASDAQ:MASI) today announced its financial results for the third quarter of 2023, ended September 30, 2023. Third Quarter 2023 Financial Results Consolidated revenue was $478.9 million, comprised of healthcare revenue of $307.8 million and non-healthcare revenue of $171.1 million. Shipments of noninvasive technology boards and instruments were 63,100. Consolidated GAAP operating income was $25.2 mi

Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release third quarter 2023 financial results for the period ended September 30, 2023, after the market closes on Tuesday, November 7, 2023. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about th

Second Quarter 2023 Highlights Consolidated revenue was $455.3 million; Healthcare revenue was $281.1 million; Non-healthcare revenue was $174.2 million; GAAP net income per diluted share was $0.29; and Non-GAAP net income per diluted share was $0.62. Masimo Corporation (NASDAQ:MASI) today announced its financial results for the second quarter of 2023, ended July 1, 2023. Second Quarter 2023 Financial Results Consolidated revenue was $455.3 million, comprised of healthcare revenue of $281.1 million and non-healthcare revenue of $174.2 million. Shipments of noninvasive technology boards and instruments were 64,100. Consolidated GAAP operating income was $29.3 millio

Management to announce and discuss complete second quarter 2023 financial results on Tuesday, August 8, 2023. Masimo Corporation (NASDAQ:MASI) today announced preliminary revenue results for the second quarter ended July 1, 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230717088647/en/(Graphic: Business Wire) Preliminary Second Quarter 2023 Revenue Results Masimo expects its consolidated revenue for the second quarter 2023 to range from $453 million to $457 million, with healthcare revenue expected to range from $280 million to $282 million and non-healthcare revenue expected to range from $173 million to $175 million

First Quarter 2023 Highlights Consolidated revenue was $565.0 million; Healthcare revenue was $346.7 million, representing 14.0% reported growth and 15.8% constant currency growth; Non-healthcare revenue was $218.3 million; GAAP earnings per diluted share was $0.39; and Non-GAAP earnings per diluted share was $0.87. Masimo (NASDAQ:MASI) today announced its financial results for the first quarter of 2023, ended April 1, 2023. First Quarter 2023 Financial Results Consolidated revenue was $565.0 million, representing 85.7% reported growth compared to $304.2 million in the first quarter of 2022. Healthcare revenue was $346.7 million, which represents 14.0% reported growth

Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release first quarter 2023 financial results for the period ended April 1, 2023, after the market closes on Tuesday, May 9, 2023. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the call wil

Fourth Quarter 2022 Highlights: Consolidated revenue was $617.0 million; Healthcare revenue was $351.9 million, representing 7.4% reported growth and 10.1% constant currency growth; and Non-healthcare revenue was $265.1 million. Full-Year 2022 Highlights: Consolidated revenue was $2,035.8 million; Healthcare revenue was $1,340.3 million, representing 8.2% reported growth and 10.6% constant currency growth; and Non-healthcare revenue was $695.5 million. Masimo (NASDAQ:MASI) today announced its financial results for the fourth quarter and full-year ended December 31, 2022. Fourth Quarter 2022 Results: Consolidated revenue was $617.0 million, representing 88.3% reported growt

Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release fourth quarter and FY 2022 financial results for the period ended December 31, 2022, after the market closes on Tuesday, February 28, 2023. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders ab

Third Quarter 2022 Highlights Consolidated revenue was $549 million; Healthcare revenue was $327 million, representing 6% reported growth and 10% constant currency growth; and Non-healthcare revenue was $222 million. Masimo (NASDAQ:MASI) today announced its financial results for the third quarter of 2022, ended October 1, 2022. Third Quarter 2022 Financial Results Consolidated revenue was $549.3 million, representing 78.7% reported growth compared to $307.4 million in the third quarter of 2021. Healthcare revenue was $327.2 million, which represents 6.4% reported growth and 10.0% growth on a constant currency basis. Non-healthcare revenue was $222.1 million. Excluding handheld an

Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release third quarter 2022 financial results for the period ended October 1, 2022, after the market closes on Tuesday, November 8, 2022. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the cal

Second Quarter 2022 Highlights Consolidated revenue was $565 million; Healthcare revenue was $357 million, representing 17% reported growth and 19% constant currency growth; Non-healthcare revenue was $208 million; and Repurchased 3 million shares of Masimo common stock for $401 million. Masimo (NASDAQ:MASI) today announced its financial results for the second quarter of 2022, ended July 2, 2022. Second Quarter 2022 Financial Results Consolidated revenue was $565.3 million, representing 85.3% reported growth compared to $305.1 million in the second quarter of 2021. Healthcare revenue was $357.0 million, which represents 17.0% reported growth and 19.0% constant currency growth on

Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release second quarter 2022 financial results for the period ended July 2, 2022, after the market closes on Tuesday, August 9, 2022. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the call wi

First Quarter 2022 Highlights Revenue was $304 million; GAAP net income per diluted share was $0.81; and Non-GAAP net income per diluted share was $0.93. Masimo (NASDAQ:MASI) today announced its financial results for the first quarter of 2022, ended April 2, 2022. First Quarter 2022 Results Revenue was $304.2 million, which represents 1.7% reported growth and 3.2% growth on a constant currency basis, compared to $299.0 million in the first quarter of 2021. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 75,700 in the first quarter of 2022. GAAP operating margin for the first quarter of 2022 was 19.6% compared to 22

Complete first quarter 2022 financial results will be announced on Tuesday, May 3, 2022. Masimo Corporation (NASDAQ:MASI) today announced certain preliminary financial results for the first quarter ending April 2, 2022 and reaffirmed its full-year 2022 revenue guidance. Preliminary First Quarter 2022 Results: Masimo expects its product revenue for the first quarter of 2022 will range from $285 million to $315 million. Shortages of critical components in combination with other supply chain issues, including freight carrier delays, have led to lower than expected sales in the first quarter. Joe Kiani, Chairman and CEO of Masimo, said, "In prior quarters, we were able to weather the storm

Fourth Quarter 2021 Highlights: Product revenue increased 11.0% to $327.6 million, GAAP net income per diluted share was $1.18; and Non-GAAP net income per diluted share was $1.21. Full-Year 2021 Highlights: Product revenue increased 8.3% to $1,239.2 million, GAAP net income per diluted share was $3.98; and Non-GAAP net income per diluted share was $3.99. Masimo (NASDAQ:MASI) today announced its financial results for the fourth quarter and full-year ended January 1, 2022. Fourth Quarter 2021 Results: Product revenue increased 11.0% to $327.6 million, or 11.5% on a constant currency basis, compared to $295.1 million in the fourth quarter of 2020. Excluding handheld and fing

Complete fourth quarter and full-year 2021 financial results will be announced on Tuesday, February 15, 2022  Preliminary full-year 2021 product revenue of approximately $1,235 million to $1,240 million; Preliminary full-year 2021 GAAP earnings per diluted share and non-GAAP earnings per diluted share are expected to exceed guidance of $3.88 and $3.88, respectively; and Full-year 2022 financial guidance for product revenue, GAAP earnings per diluted share and non-GAAP earnings per diluted share of approximately $1,350 million, $4.27 and $4.34, respectively. Masimo Corporation (NASDAQ:MASI) today announced select preliminary financial and operational results for the full-year ended

Third Quarter 2021 Highlights Product revenue was $307.4 million; GAAP net income per diluted share was $1.00; and Non-GAAP net income per diluted share was $0.94. Masimo (NASDAQ:MASI) today announced its financial results for the third quarter of 2021, ended October 2, 2021. Third Quarter 2021 Results Product revenue was $307.4 million, which represents 10.5% reported growth and 10.1% growth on a constant currency basis, compared to $278.1 million in the third quarter of 2020. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 74,600 in the third quarter of 2021. GAAP operating margin for the third quarter 2021 was 2

Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release third quarter 2021 financial results for the period ended October 2, 2021, after the market closes on Tuesday, October 26, 2021. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with call details and a registrant ID number. Reminders about the call will also be sent to r

Second Quarter 2021 Highlights Product revenue was $305.1 million; GAAP net income per diluted share was $0.88; and Non-GAAP net income per diluted share was $0.94.   Masimo (NASDAQ:MASI) today announced its financial results for the second quarter of 2021, ended July 3, 2021. Second Quarter 2021 Results: Product revenue increased 1.4% to $305.1 million, and decreased 0.1% on a constant currency basis, compared to $301.0 million in the second quarter of 2020. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 72,500 in the second quarter of 2021. GAAP operating margin for the second quarter 2021 was 21.3% compared t

First Quarter 2021 Highlights Product revenue increased 10.9% to $299.0 million, or 9.5% on a constant currency basis; GAAP net income per diluted share was $0.92; and Non-GAAP net income per diluted share was $0.90. Masimo (NASDAQ:MASI) today announced its financial results for the first quarter of 2021, ended April 3, 2021. First Quarter 2021 Results: Product revenue increased 10.9% to $299.0 million, or 9.5% on a constant currency basis, compared to $269.6 million in the first quarter of 2020. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 66,000 in the first quarter of 2021, compared to 72,100 in the first qua

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (Nasdaq: MASI) today announced its financial results for the fourth quarter and full-year ended January 2, 2021. Fourth Quarter 2020 Results: Total revenue for the fourth quarter of 2020, including royalty and other revenue, increased 19.2% to $295.1 million, compared to $247.5 million in the fourth quarter of 2019. Product revenue increased 19.2% to $295.1 million, or 18.1% on a constant currency basis, compared to $247.4 million in the fourth quarter of 2019. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments increased 35.2% to 83,000 in the fourth quarter of 2020, compared to 61,40